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Abstract
Dental management of osteoporosis patients on anti-resorptive therapy can be challenging for both 
the dentist and physician because of the risk of osteonecrosis of the jaw (ONJ). This editorial 
reflects on the paper written by Tagushi et al that expressed a relative lack of communication 
between health care providers when treating osteoporosis patients. Osteoporosis-related bone 
fractures can be debilitating and occasionally lethal, but management with anti-resorptives is vital 
while cognizant of the complication of ONJ that can also negatively impact patient’s quality of 
life.
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A common African proverb states that ‘when two elephants fight, it is the grass that suffers’. 
Which means that the foot stamping that goes on back and forth between the fighting 
animals will destroy the grass leaving an indelible patch of barren land within the grassland. 
When considering the issues of osteoporosis, anti-resorptive therapies and the complication 
of osteonecrosis of the jaw (ONJ), it is not a case of just ‘two elephants’ but three. So if 
these three are not properly balanced, patient’s health and quality of life will be 
compromised.
Osteoporosis is a major skeletal disorder that affects over 10 million individuals worldwide1. 
It is projected that healthcare burden of osteoporosis will rise astronomically by 2050 due to 
the aging population1. Many osteoporosis patients are treated with anti-resorptive drugs such 
as bisphosphonates and denosumab, both of which have been associated with the 
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complication of ONJ. Anti-resorptives are highly efficacious and have been used successful 
in the management of osteoporosis and skeletal events of cancer metastasis2, 3. They also 
provide many drug options to choose from as well as different dosing regimens. 
Unfortunately ONJ is a major complication of anti-resorptives4–6. It is recalcitrant and 
unpredictable, which has alarmed the medical community to prescribe anti-resorptives with 
caution. There is still no clear understanding of ONJ pathophysiology, and management 
regimens are still confusing at best7, 8
The increasing incidence of osteoporosis due to the aging population combined with the 
reliance on anti-resorptive therapies means a balance must be struck to improve osteoporosis 
while limiting the occurrence of ONJ so patient outcomes can be improved. Many local and 
systemic etiological factors that promote osteoporosis also induce alveolar bone loss9; hence 
the direct effects of osteoporosis coupled with administration of anti-resorptive drugs further 
heighten the concerns about ONJ. There is a need to balance osteoporosis therapy with 
prevention of ONJ, but this has caused several controversies between different medical and 
dental professionals. Some have proposed that withdrawal or dose reduction of anti-
resorptive therapy will reduce the incidence of ONJ10–12 but this theory has not been clearly 
proven. Notwithstanding, some dental healthcare providers as reported by Tagushi et al often 
request physicians to withdraw anti-resorptive therapy before major dental procedures13. 
Unfortunately, this approach increases the chances of causing adverse events of osteoporosis 
including skeletal fractures that will further jeopardize the health of the patient.
The paper by Tagushi et al highlight the possibility that lack of cooperation between 
physicians and dentists during the management of osteoporosis may in fact cause an increase 
in osteoporosis related fractures and ONJ13. In a previous study the authors used a 
questionnaire-based survey of Japanese physicians and determined that discontinuation of 
anti-resorptives before dental extractions increased adverse events of osteoporosis but did 
not prevent the development of ONJ14. As this study was conducted among physicians in 
private clinics with limited sample size (n = 209), the authors conducted a follow up study 
using a larger sample size (n = 629) of physicians in an academic environment13. The paper 
reported that many Japanese dentists continued to request discontinuation of anti-resorptives 
before dental extractions. The authors also showed that there were 3.6% and 0.7% cases of 
osteoporosis-related adverse events and ONJ respectively within 3 months of discontinuing 
the use of anti-resorptives. However these increased to 5.3% and 1.6% respectively when the 
anti-resorptives were discontinued for more than 3 months13.
The confounding factor was that 62% of respondents did not request dental evaluation prior 
to commencement of anti-resorptive therapy, which made it unclear whether this had an 
impact on the outcome of dental extractions performed after discontinuation of anti-
resorptives. The authors also stated that physicians who refused discontinuation of anti-
resorptives did not report any case of ONJ but it was also not clear whether these patients 
received routine dental care before and during the use of anti-resorptives.
In spite of the confounding factors, Tagushi et al concluded that these results supported their 
earlier data and strengthens the assertion that cooperation between physicians and dentists 
treating patients with osteoporosis is vital to prevention of both osteoporosis related 
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fractures and ONJ13. Additionally, these results also clearly emphasize the limited value of 
the ‘drug holiday’ theory that discontinuation of anti-resorptives will reduce occurrence of 
ONJ. Another cogent point from this study is the reported lack of cooperation between 
physician and dentists when managing osteoporosis patients. Since treatment guidelines 
have been established by several medical and dental societies and academies15, 16, a clear 
communication between physicians and dentists should foster sharing of information on 
current management regimens for both osteoporosis and ONJ. Just as ‘two fighting elephants 
cause the grass to wither’, lack of communication between physicians and dentists managing 
osteoporosis patients may hamper patient care outcomes. It is vital to keep the lines of 
communications open among healthcare providers when managing patients with 
osteoporosis.
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